Protalix Retained Earnings vs Net Tangible Assets Analysis
PLX Stock | USD 1.14 0.02 1.72% |
Protalix Biotherapeutics financial indicator trend analysis is much more than just breaking down Protalix Biotherapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Protalix Biotherapeutics is a good investment. Please check the relationship between Protalix Biotherapeutics Retained Earnings and its Net Tangible Assets accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Protalix Biotherapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Protalix Stock please use our How to Invest in Protalix Biotherapeutics guide.
Retained Earnings vs Net Tangible Assets
Retained Earnings vs Net Tangible Assets Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Protalix Biotherapeutics Retained Earnings account and Net Tangible Assets. At this time, the significance of the direction appears to have no relationship.
The correlation between Protalix Biotherapeutics' Retained Earnings and Net Tangible Assets is 0.08. Overlapping area represents the amount of variation of Retained Earnings that can explain the historical movement of Net Tangible Assets in the same time period over historical financial statements of Protalix Biotherapeutics, assuming nothing else is changed. The correlation between historical values of Protalix Biotherapeutics' Retained Earnings and Net Tangible Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Retained Earnings of Protalix Biotherapeutics are associated (or correlated) with its Net Tangible Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Tangible Assets has no effect on the direction of Retained Earnings i.e., Protalix Biotherapeutics' Retained Earnings and Net Tangible Assets go up and down completely randomly.
Correlation Coefficient | 0.08 |
Relationship Direction | Positive |
Relationship Strength | Insignificant |
Retained Earnings
The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.Net Tangible Assets
The total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company.Most indicators from Protalix Biotherapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Protalix Biotherapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Protalix Biotherapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Protalix Stock please use our How to Invest in Protalix Biotherapeutics guide.At this time, Protalix Biotherapeutics' Selling General Administrative is fairly stable compared to the past year. Tax Provision is likely to rise to about 287.5 K in 2024, despite the fact that Discontinued Operations is likely to grow to (206.5 K).
2021 | 2022 | 2023 | 2024 (projected) | Total Revenue | 38.4M | 47.6M | 65.5M | 68.8M | Depreciation And Amortization | 401K | 2.2M | 1.2M | 1.7M |
Protalix Biotherapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Protalix Biotherapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Protalix Biotherapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 45.4M | 67.9M | 73.7M | 55.8M | 84.4M | 51.0M | |
Other Current Liab | 11.9M | 13.9M | 16.4M | 12.3M | 16.7M | 17.5M | |
Total Current Liabilities | 40.2M | 86.5M | 33.2M | 32.4M | 45.5M | 47.8M | |
Net Debt | 43.1M | 46.1M | (5.5M) | 16.4M | 2.6M | 2.8M | |
Cash | 17.8M | 18.3M | 39.0M | 17.1M | 23.6M | 31.8M | |
Non Current Assets Total | 12.9M | 12.2M | 12.0M | 10.9M | 14.5M | 9.6M | |
Cash And Short Term Investments | 17.8M | 38.5M | 39.0M | 22.2M | 44.6M | 33.7M | |
Net Receivables | 4.7M | 2M | 3.4M | 4.6M | 5.3M | 3.1M | |
Common Stock Shares Outstanding | 14.8M | 29.1M | 44.1M | 48.5M | 82.4M | 86.5M | |
Liabilities And Stockholders Equity | 45.4M | 67.9M | 73.7M | 55.8M | 84.4M | 51.0M | |
Non Current Liabilities Total | 75.5M | 8.5M | 46.5M | 34.0M | 5.3M | 5.1M | |
Other Current Assets | 698K | 2.1M | 1.3M | 536K | 1.1M | 1.6M | |
Total Liab | 115.7M | 95.0M | 79.7M | 66.4M | 50.9M | 56.1M | |
Total Current Assets | 32.5M | 55.7M | 61.7M | 44.9M | 69.9M | 42.5M | |
Short Long Term Debt Total | 60.9M | 64.4M | 33.5M | 33.5M | 26.3M | 51.0M | |
Total Stockholder Equity | (70.3M) | (27.0M) | (6.0M) | (10.6M) | 33.6M | 35.2M | |
Property Plant And Equipment Net | 11.0M | 10.4M | 9.9M | 9.6M | 10.9M | 10.5M | |
Retained Earnings | (340.8M) | (347.4M) | (374.9M) | (389.9M) | (381.5M) | (362.5M) | |
Non Currrent Assets Other | 2.0M | 1.8M | 2.1M | 1.3M | 528.0K | 501.6K | |
Common Stock Total Equity | 144K | 148K | 15K | 35K | 40.3K | 62.7K | |
Other Stockholder Equity | 270.5M | 320.3M | 368.9M | 379.2M | 415.0M | 435.8M | |
Short Term Debt | 5.4M | 59.9M | 1.2M | 1.1M | 21.7M | 16.5M | |
Common Stock | 15K | 35K | 46K | 54K | 73K | 62.8K | |
Accounts Payable | 6.5M | 7.2M | 7.0M | 5.9M | 4.3M | 4.3M | |
Short Term Investments | 26K | 20.3M | 39.0M | 5.1M | 20.9M | 22.0M | |
Other Assets | 2.0M | 7.4K | 2.1M | 1.3M | 1.0 | 0.95 | |
Other Liab | 20.1M | 4.0M | 14.3M | 1.6M | 1.5M | 1.4M | |
Property Plant Equipment | 5.3M | 10.4M | 9.9M | 9.6M | 8.7M | 8.1M | |
Current Deferred Revenue | 16.3M | 5.4M | 8.6M | 13.2M | 2.9M | 2.7M | |
Inventory | 8.2M | 13.1M | 18.0M | 16.8M | 19.0M | 9.6M | |
Net Tangible Assets | (70.3M) | (27.0M) | (6.0M) | (10.6M) | (9.6M) | (10.1M) | |
Long Term Debt | 51.0M | 51K | 27.9M | 28.2M | 25.4M | 28.8M | |
Capital Surpluse | 270.5M | 320.3M | 368.9M | 379.2M | 436.0M | 272.0M | |
Non Current Liabilities Other | 5.1M | 5.3M | 75.5M | 51K | 45.9K | 43.6K | |
Long Term Debt Total | 51.5M | 51K | 27.9M | 28.2M | 25.4M | 28.3M | |
Net Invested Capital | (15.1M) | 31.5M | 21.9M | 17.5M | 53.8M | 56.5M |
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Protalix Biotherapeutics using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Protalix Biotherapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Protalix Stock please use our How to Invest in Protalix Biotherapeutics guide.You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Complementary Tools for Protalix Stock analysis
When running Protalix Biotherapeutics' price analysis, check to measure Protalix Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protalix Biotherapeutics is operating at the current time. Most of Protalix Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Protalix Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protalix Biotherapeutics' price. Additionally, you may evaluate how the addition of Protalix Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |
Is Protalix Biotherapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Protalix Biotherapeutics. If investors know Protalix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Protalix Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.39) | Earnings Share 0.09 | Revenue Per Share 0.97 | Quarterly Revenue Growth 0.217 | Return On Assets 0.0933 |
The market value of Protalix Biotherapeutics is measured differently than its book value, which is the value of Protalix that is recorded on the company's balance sheet. Investors also form their own opinion of Protalix Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Protalix Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Protalix Biotherapeutics' market value can be influenced by many factors that don't directly affect Protalix Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Protalix Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Protalix Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Protalix Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.